Hudson Bay Capital Management’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
Other funds holding CYTK
ACA
Hudson Bay Capital Management's CYTK Position: Q2 2026 in Review
Hudson Bay Capital Management reduced its Cytokinetics (CYTK) stake by 24% in Q2 2026, selling an estimated $680K and leaving 30,000 shares worth $2.56M. The position accounts for 0.01% of the portfolio, ranked #756.
Hudson Bay Capital Management first reported a position in CYTK in Q4 2019 and has held it in 15 quarters since. The position peaked at $17.4M in Q1 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.
- Hudson Bay Capital Management held 30,000 shares of Cytokinetics worth $2.56M as of Q2 2026.
- Hudson Bay Capital Management sold 9,470 Cytokinetics shares in Q2 2026, an estimated $680K.
- Cytokinetics made up 0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #756 holding.
- Hudson Bay Capital Management first reported a position in Cytokinetics in Q4 2019 and has held it in 15 quarters since.
- Hudson Bay Capital Management's Cytokinetics position peaked at $17.4M in Q1 2024.
- 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.
Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.